The present and future of prostate cancer urine biomarkers

Marina Rigau, Mireia Olivan, Marta Garcia, Tamara Sequeiros, Melania Montes, Eva Colás, Marta Llauradó, Jacques Planas, Inés de Torres, Juan Morote, Colin Cooper, Jaume Reventós, Jeremy Clark, Andreas Doll

Producció científica: Contribució a una revistaArticle de revisióRecercaAvaluat per experts

58 Cites (Scopus)

Resum

In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. In recent years, the utilization of urine has emerged as an attractive option for the non-invasive detection of PCa. Moreover, a great improvement in high-throughput "omic" techniques has presented considerable opportunities for the identification of new biomarkers. Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field. © 2013 by the authors; licensee MDPI, Basel, Switzerland.
Idioma originalEnglish
Pàgines (de-a)12620-12649
RevistaInternational Journal of Molecular Sciences
Volum14
Número6
DOIs
Estat de la publicacióPublicada - 1 de gen. 2013

Fingerprint

Navegar pels temes de recerca de 'The present and future of prostate cancer urine biomarkers'. Junts formen un fingerprint únic.

Com citar-ho